RNS Number : 0919Q
Iconic Labs PLC
13 October 2023

13 October 2023

Iconic Labs PLC

("Iconic" or the "Company")

Announcement of the Completion of CVA

Iconic Labs PLC (LSE: ICON) is pleased to announce that the Creditors Voluntary Arrangement ("CVA") has been completed and the relevant documents have been filed at and accepted by Companies House.

Brad Taylor, Chief Executive Officer of Iconic Labs, commented:

"The successful completion of the CVA marks an important step towards Iconic Labs' financial stability. Now that the CVA is discharged, Iconic Labs has removed historic debts and is well positioned to progress with growth opportunities and focus on its strategic goals.

"We look forward to updating shareholders and the market on our further activity in due course."

- Ends -

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 as it forms part of UK domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"), and is disclosed in accordance with the Company's obligations under Article 17 of MAR.

For any further information or enquiries please contact:

Iconic Labs

Brad Taylor, Chief Executive Officer

Tel: +44 (0) 7462 156238

ir@iconiclabs.co.uk

Novum Securities Limited

David Coffman / Daniel Harris

Tel: +44 (0) 20 7399 9400

Yellow Jersey PR

Sarah Hollins

Annabelle Wills

Bessie Elliot

Tel: +44 (0) 20 3004 9512

iconic@yellowjerseypr.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
ARINKNBNKBDDKKD